MoonLake Immunotherapeutics (MLTX) Form 424B5 — Jun 24, 2026
MoonLake Immunotherapeutics is pricing a public offering of 9,000,000 Class A Ordinary Shares and pre-funded warrants to purchase 1,000,000 shares at a public offering price of $20.00 per share. The transaction is expected to generate gross proceeds of approximately $199.9 million, with underwriters granted a 30-day option to purchase up to 1,500,000 additional shares. The company plans to use the net proceeds of roughly $189 million to fund the research, development, and commercialization of its lead asset Sonelokimab (SLK). Management estimates that the capital raised, combined with existing cash, will be sufficient to fund operations and capital expenditures through mid-2028.
Key figures
- Greenshoe
- 1,500,000
- Gross Proceeds
- $199,999,900
- Offering Price
- $20.00
- Shares Offered
- 9,000,000
- Warrants offered
- 1,000,000
- Net proceeds estimated
- $188,999,900
- Warrant exercise price
- $0.0001
Price after filing
Close on the filing date to close N calendar days later (from $20.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.